. Thus all our acid-treated samples gave higher values. Accurate determination of lysozyme in biological fluids should therefore take these variables into consideration. In this investigation we determined unbound and released lysozyme in parotid fluid samples of normal donors under standardized experimental conditions: acidification, which released the bound lysozyme; centrifugation, which eliminated the proteins present; and neutralization of the supernatant fluid to the original pH of the parotid saliva. This standardized procedure can be used for studying alterations in the concentration of lysozyme in parotid saliva that may be caused by various exogenous and endogenous factors or conditions such as eating, drinking, or smoking before sample collection; inflammation or infection in the oral cavity; and hormonal variations and systemic diseases. Thus the role of lysozyme in parotid saliva can be better understood. Although an increase of LDH 1 in sera of patients with seminoma was reported (2,3), I could not find a quantitative estimation of this isoenzyme in patients with testicular tumors. Therefore, I report here a patient with seminoma whose serum LDH 1 represented a very high percentage of his total LDH activity.
. Thus all our acid-treated samples gave higher values. Accurate determination of lysozyme in biological fluids should therefore take these variables into consideration. In this investigation we determined unbound and released lysozyme in parotid fluid samples of normal donors under standardized experimental conditions: acidification, which released the bound lysozyme; centrifugation, which eliminated the proteins present; and neutralization of the supernatant fluid to the original pH of the parotid saliva. This standardized procedure can be used for studying alterations in the concentration of lysozyme in parotid saliva that may be caused by various exogenous and endogenous factors or conditions such as eating, drinking, or smoking before sample collection; inflammation or infection in the oral cavity; and hormonal variations and systemic diseases. Thus the role of lysozyme in parotid saliva can be better understood. Although an increase of LDH 1 in sera of patients with seminoma was reported (2,3), I could not find a quantitative estimation of this isoenzyme in patients with testicular tumors. Therefore, I report here a patient with seminoma whose serum LDH 1 represented a very high percentage of his total LDH activity.
A 26-year-old black man had a histopathologically proven seminoma, without detectable metastases. His total LDH activity (SMA-ll/C Analyzer; Technicon Corp., Tarrytown, NY 10591) exceeded 3000 U/L at 37 #{176}C (reference interval, 100 to 250 UfL). LDH isoenzymes were electrophoretically separated (ACI; Corning Modfield, MA 02052). The supporting medium was a thin layer of agarose, the buffer was sodium diethyl barbiturate (50 mmol/L, pH 8.6). The LDH isoenzyme, quantitated by densitometry (densitometer Model CDS-200, 520 nm; Beckman, Fullerton, CA 92634), revealed LDH 1,82% (reference interval, 13-25%); LDH 2, 13%; LDH 3, 3%; and LDH 4 and LDH 5,1%, respectively. The concentrationof human choriogonadotropin in serum (undetectable in healthy males) was 11 mt.unitsfL and alpha-fetoprotein was not detectable by RIA (<40 pgfL). The aspartate aminotransferase and alanine aminotransferase activities were respectively 56 and 59 UfL at 37#{176}C (reference interval, 5-40 U/L). After surgery, the total LDH activity gradually decreased (1765, 1265, 1070, 700, and 640 U/L on five consecutive days). The LDH isoenzymes always showed a predominance of LDH 1(83-85% of total LDH activiIn contrast to the patient just described, a 23-year-old man with an embryonal type (non-semmomatous) testicular tumor showed only a slight increase of serum LDH activity (343 U/L) before surgery, with a LDH isoenzyme pattern similar to the reference pattern (i.e., LDH 2 was in the highest percentage). The percentage of serum LDH 1 seen in the patient with seminoma just described is, to my knowledge, the highest reported. Although the increase of total LDH activity in serum of patients with testicular tumor was described and its measurement was used to follow up patients with such tumors after treatment (3, 4), LDH isoenzyme percentages were not reported (2-4). Recently, it was shown that an LDH-1 percentage exceeding 37.2% correlates with the extent of the disease, but patients with pure seminoma do not have increased LDH 1 except in advanced stages (3). I assume that the seminoma in my patient secreted only LDH 1, which could explain the very high percentage of this enzyme in serum. This is in contrast to most tumors, which contain mainly cathodal LDH isoenzymes (5). The post-pubertal human testis has a sixth LDH isoenzyme (LDH), migrating between LDH 3 and LDH 4. In a homogenate (in the buffer just described) of a normal testis collected at autopsy, I found that LDH 1 was 5%; LDH 2, 20; LDH 3 and LDHX, 41%; LDH 4,25%; and LDH 5, 9% of total LDH activity. A review of the literature showed that medullary rays of the kidney have up to 60% LDH 1, the heart 35 to 71%, and erythrocytes 36 to 46%, according to various methods of separation (6). The highest LDH 1 percentage so far found in serum, 72% of total LDH, was reported in a patient with rapidly progressive malignant teratoma in the anterior mediastinwn
(7).
Possibly seminoma tissue has a genetic alteration, which influences the synthesis of various isoenzymes. Increased inactive CK-B was reported in plasma of patients with seminoma (8). Whether LDH 1 produced by the seminoma has the same antigenicity as the "normal" serum LDH 1 remains to be investigated. Like PP, they contain 36 amino acid residues. PYY has four prolyl residues at positions 2,5,8, and 14, which are also highly conserved in mainmalian and avian PP (3, 4) , suggesting that the three-dimensional structure (5) may be an important characteristic of the peptides. NPY also contains four prolyl residues (2). 
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Four antisera to PP were used in this study. Those designated anti-HPP serum (615-1054B-248-19 ) and antiBPPserum (615-R110-146-6) were provided by Dr. Chance. Antibody PP205 was raised to BPP by methods described elsewhere (7). Antibody PP221 was raised to the C-terminal hexapeptide of PP (1 mg) conjugated to rabbit albumin (8 mg) by means of difluorodinitrobenzene.
The final dilutions of antisera for radioimmunoassay were 1:600 000 (anti-HPP serum), 1:800000 (anti-BPP serum), 1:72 000 (PP205), and 1:64 000 (PP221), with use of labeled BPP. The Queen's University of Belfast radioimmunoassay procedure: lmIla beled BPP was prepared by use of Chloramine T and purified by anionexchange chromatography on QAE Sephadex A-25. Details of assay procedures are described elsewhere (7).
University of Cincinnati Radioimmunoassay procedure: Methods described previously (8,9) were used to prepare 'I-labeled PPP and purify it by cation-exchange chromatography on SP Sephadex, and in the manipulation of assay mixtures.
With the assay developed in Belfast, HPP displaced radiolabeled BPPmore efficiently from the antibody raised to BPP (PP205) than that raised to the Cterminal hexapeptide (PP221). PYY reacted only slightly with PP221 and not at all with PP205 (Figure 1) . In this assay system, PYY did not react with anti-HPP or anti-BPP serum supplied by Dr. Chance. Furthermore, NPY reacted with none of the four antisera. Similarly, no cross reactivity was detected on using the Cincinnati assay and antisera provided by Dr. Chance, as typified by the results shown in Figure 2 .
The lack of cross reactivity of the new peptides, PYY and NPY, with the available antisera for PP is fortuitous considering the extensive homology between the peptides. While the results give credence to data on PP obtained by radioimmunoassay, this_cannot be extended to immunohistochemical studies. PP-like immunoreactivity 
